Form 10-Q Centessa Pharmaceuticals For: Mar 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022. | May 16, 2022
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
- Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones - - SerpinPC registration studies planned to begin in 2H 2022 following
30.03.2022 - – Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on .